Clinical studies of VEGF inhibitors in MM predominantly involve combinations with PD-1 inhibitors and show promising results such as objective response rates (ORR) of about 40–45% in early studies [123,182]. The gene discussed is VEGFA; the disease is Miyoshi myopathy.